Purple Biotech (PPBT) Stock Price, News & Analysis

Company Overview

Purple Biotech Ltd. (NASDAQ: PPBT) is a clinical-stage biopharmaceutical company focused on developing therapies for cancer. The company’s research programs are designed to address mechanisms that can limit the effectiveness of existing immunotherapies and other cancer treatments.

Purple Biotech’s principal investigational programs have included CM24, an antibody intended to target CEACAM1 and enhance antitumor immune responses, and NT219, a small-molecule treatment candidate designed to interfere with signaling pathways associated with cancer-cell survival and resistance to therapy. These programs have been evaluated in combination with established oncology treatments, including immune checkpoint inhibitors.

The company was formerly known as Kitov Pharmaceuticals and adopted the Purple Biotech name in 2020. Under its former name, the company also developed Consensi, a fixed-dose combination of celecoxib and amlodipine that received approval from the U.S. Food and Drug Administration for patients with osteoarthritis and hypertension. Purple Biotech is based in Israel and has conducted its development activities through international clinical programs, including work involving the United States.

Key Stats

• Today's Range: $1.40 to $1.54
• 50-Day Range: $1.33 to $1.98
• 52-Week Range: $1.16 to $14.10
• Volume: 32,137 shs
• Average Volume: 562,813 shs
• Market Capitalization: $1.36 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $30.00
• Consensus Rating: Hold

Purple Biotech Stock Analysis - MarketRank™

Purple Biotech scored higher than 41% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Purple Biotech has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.

Upside Potential

Purple Biotech has a consensus price target of $30.00, representing about 1,946.4% upside from its current price of $1.47.

Amount of Analyst Coverage

Purple Biotech has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Purple Biotech are expected to grow in the coming year, from ($5.73) to ($1.01) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Purple Biotech is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Purple Biotech is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Purple Biotech has a P/B Ratio of 0.14. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.12% of the float of Purple Biotech has been sold short.

Short Interest Ratio / Days to Cover

Purple Biotech has a short interest ratio ("days to cover") of 0.91, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Purple Biotech has recently increased by 7.51%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Purple Biotech does not currently pay a dividend.

Dividend Growth

Purple Biotech does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Purple Biotech this week, compared to 1 article on an average week.

Search Interest

3 people have searched for PPBT on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Purple Biotech insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.98% of the stock of Purple Biotech is held by insiders.

Percentage Held by Institutions

9.64% of the stock of Purple Biotech is held by institutions.

Company Calendar

• Last Earnings: 8/07/2026
• Today: 9/21/2026
• Next Earnings (Estimated): 11/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:PPBT
• Previous Symbol: NASDAQ:KTOV
• CIK: 1614744
• Web: purple-biotech.com
• Phone: (723) 933-3121
• Fax: 972-153-39333121
• Employees: 10
• Year Founded: 1968

Price Target and Rating

• Average Price Target for Purple Biotech: $30.00
• High Price Target: $30.00
• Low Price Target: $30.00
• Potential Upside/Downside: +1,957.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($23.25)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$26.39 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -147.77%
• Return on Assets: -111.59%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.70
• Quick Ratio: 3.70

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $10.39 per share
• Price / Book: 0.14

Miscellaneous

• Outstanding Shares: 929,000
• Free Float: 901,000
• Market Cap: $1.35 million
• Optionable: Optionable
• Beta: 0.71